Cochrane · systematic review · CD013433
Stem cell therapy for dilated cardiomyopathy
Diaz-Navarro, R, Urrútia, G, Cleland, JGF, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 3 · 23.1%Very low 6 · 46.2%Low 4 · 30.8%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Stem cell therapy compared to control for dilated cardiomyopathy
Population: DCM (non‐ischaemic)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Stem cell therapy vs control | RR 0.84 [0.54, 1.31] | 7 studies · 361 participants | Very low Downgraded: risk of bias, imprecision |
Procedural complications Within 30 days Stem cell therapy vs control | no estimate extracted | 7 studies · 361 participants | Very low Downgraded: risk of bias, inconsistency |
Health‐related quality of life Stem cell therapy vs control | no estimate extracted | 5 studies · 272 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Performance status – 6MWT (m) Stem cell therapy vs control | no estimate extracted | 5 studies · 230 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Performance status – change in functional class (NYHA) Stem cell therapy vs control | no estimate extracted | 6 studies · 398 participants | Low Downgraded: risk of bias, indirectness |
MACE Stem cell therapy vs control | no estimate extracted | 0 studies · 0 participants | Ungraded |
Ventricular arrhythmia Stem cell therapy vs control | no estimate extracted | 8 studies · 504 participants | Low Downgraded: risk of bias, indirectness |
Stem cell therapy (any type) compared to peripheral therapy with granulocyte colony‐stimulating factor for dilated cardiomyopathy
Population: DCM (non‐ischaemic)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Stem cell therapy (any type) vs peripheral therapy with granulocyte colony‐stimulating factor | RR 0.46 [0.16, 1.31] | 3 studies · 195 participants | Very low Downgraded: risk of bias, inconsistency, indirectness |
Procedural complications (safety) Stem cell therapy (any type) vs peripheral therapy with granulocyte colony‐stimulating factor | no estimate extracted | 1 study · 60 participants | Very low Downgraded: imprecision, indirectness |
Health‐related quality of life Stem cell therapy (any type) vs peripheral therapy with granulocyte colony‐stimulating factor | no estimate extracted | 1 study · 22 participants | Low Downgraded: imprecision |
Performance status – functional class (NYHA) Stem cell therapy (any type) vs peripheral therapy with granulocyte colony‐stimulating factor | no estimate extracted | 0 studies · 0 participants | Ungraded |
Performance status – exercise tolerance (6MWT) (m) Stem cell therapy (any type) vs peripheral therapy with granulocyte colony‐stimulating factor | no estimate extracted | 2 studies · 155 participants | Low Downgraded: risk of bias, inconsistency |
MACE Stem cell therapy (any type) vs peripheral therapy with granulocyte colony‐stimulating factor | no estimate extracted | 0 studies · 0 participants | Ungraded |